Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months

NCT00775840 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00775840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00775840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2008
Enrollment
22 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure